Drug Class: Immunotherapy

Bispecific Antibodies: PD-1, LAG-3

Treatment given for recurrence occurring at any time after last platinum-based treatment

Objective Response Rate (%)

Percentage of patients whose tumors shrink or go away after treatment

Progression Free Survival (months)

Median length of time before the cancer comes back or gets worse

Prior Therapies Not Reported

Bispecific Antibodies: PD-1, LAG-3

Treatment given for recurrence occurring at any time after last platinum-based treatment

For more detailed information, please click on the clinical trial ID number.

Trial ID # Phase Drugs Clinical Trial Title Key Conclusion and Results
Drugs in Clinical Development
NCT03219268 I Tebotelimab, Margetuximab A Phase 1, First-in-Human, Open-Label, Dose Escalation Study of MGD013, A Bispecific DART® Protein Binding PD-1 and LAG-3 in Patients With Unresectable or Metastatic Neoplasms

Tebotelimab (MGD013) alone or in combination with margetuximab has an acceptable safety profile and shows encouraging early evidence of anti-tumor activity

23 ovarian in monotherapy expansion
ORR: 8.7% (2PR); DCR: 52.2% (2PR, 10SD)
Baseline LAG-3 expression and inflammatory interferon-gamma signature was associated with response

Tebotelimab+Margituximab: 41 HER2+ patients, median 2 prior therapies (1-7), 5 ovarian
28 evaluable, 3 ovarian:
ORR: 28.6% (1CR - cholangiocarcinoma, 5PR, 2uPR - 1 ovarian); DCR: 50% (1CR, 5PR, 2uPR, 6SD) - responses in PD-L1 low patients

abs May 2020 and presentation, abs Nov 2020 and poster

< Return to Drug Classes

< Return to Clinical Trial Results Homepage